These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 18558792)

  • 1. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
    Molden E; Skovlund E; Braathen P
    Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
    Bakhai A; Rigney U; Hollis S; Emmas C
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
    Milner E; Ainsworth M; Gleaton M; Bookstaver D
    J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interaction risk with statin switch].
    Molden E; Westergren T
    Tidsskr Nor Laegeforen; 2007 Feb; 127(4):428-31. PubMed ID: 17304269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
    Hoch M; Hoever P; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.
    Devold HM; Molden E; Skurtveit S; Furu K
    Br J Clin Pharmacol; 2009 Feb; 67(2):234-41. PubMed ID: 19220274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
    Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
    Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
    Geleedst-De Vooght M; Maitland-van der Zee AH; Schalekamp T; Mantel-Teeuwisse A; Jansen P
    Drugs Aging; 2010 Jul; 27(7):589-96. PubMed ID: 20583852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
    Saw J; Steinhubl SR; Berger PB; Kereiakes DJ; Serebruany VL; Brennan D; Topol EJ;
    Circulation; 2003 Aug; 108(8):921-4. PubMed ID: 12925453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.
    Tirkkonen T; Ryynänen A; Vahlberg T; Irjala K; Klaukka T; Huupponen R; Laine K
    Drug Saf; 2008; 31(3):231-40. PubMed ID: 18302447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.
    Dingemanse J; Nicolas LB; van Bortel L
    Eur J Clin Pharmacol; 2014 Jun; 70(6):675-84. PubMed ID: 24728182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
    Golomb B; Evans M
    Drug Saf; 2006; 29(12):1191; author reply 1191-2. PubMed ID: 17147465
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
    Ronaldson KJ; O'Shea JM; Boyd IW
    Drug Saf; 2006; 29(11):1061-7. PubMed ID: 17061911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.
    Zhou YT; Yu LS; Zeng S; Huang YW; Xu HM; Zhou Q
    Ther Clin Risk Manag; 2014; 10():17-26. PubMed ID: 24379677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
    Polli JW; Hussey E; Bush M; Generaux G; Smith G; Collins D; McMullen S; Turner N; Nunez DJ
    Xenobiotica; 2013 Jun; 43(6):498-508. PubMed ID: 23256625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies.
    Molden E; Garcia BH; Braathen P; Eggen AE
    Eur J Clin Pharmacol; 2005 Apr; 61(2):119-25. PubMed ID: 15692832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
    S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.